Departamento de Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil.
Br J Pharmacol. 2012 Dec;167(8):1737-52. doi: 10.1111/j.1476-5381.2012.02127.x.
Kinin B(1) and B(2) receptors have been implicated in physiological and pathological conditions of the urinary bladder. However, their role in overactive urinary bladder (OAB) syndrome following spinal cord injury (SCI) remains elusive.
We investigated the role of kinin B(1) and B(2) receptors in OAB after SCI in rats.
SCI was associated with a marked inflammatory response and functional changes in the urinary bladder. SCI resulted in an up-regulation of B(1) receptor mRNA in the urinary bladder, dorsal root ganglion and spinal cord, as well as in B(1) protein in the urinary bladder and B(1) and B(2) receptor protein in spinal cord. Interestingly, both B(1) and B(2) protein expression were similarly distributed in detrusor muscle and urothelium of animals with SCI. In vitro stimulation of urinary bladder with the selective B(1) or B(2) agonist elicited a higher concentration-response curve in the SCI urinary bladder than in naive or sham urinary bladders. Cystometry revealed that treatment of SCI animals with the B(2) selective antagonist icatibant reduced the amplitude and number of non-voiding contractions (NVCs). The B(1) antagonist des-Arg(9) -[Leu(8) ]-bradykinin reduced the number of NVCs while the non-peptide B(1) antagonist SSR240612 reduced the number of NVCs, the urinary bladder capacity and increased the voiding efficiency and voided volume.
Taken together, these data show the important roles of B(1) and B(2) receptors in OAB following SCI in rats and suggest that blockade of these receptors could be a potential therapeutic target for controlling OAB.
激肽 B(1)和 B(2)受体参与了膀胱的生理和病理状态。然而,它们在脊髓损伤(SCI)后逼尿肌过度活动症(OAB)中的作用仍不清楚。
我们研究了激肽 B(1)和 B(2)受体在 SCI 大鼠 OAB 中的作用。
SCI 与膀胱的炎症反应和功能变化有关。SCI 导致膀胱、背根神经节和脊髓中 B(1)受体 mRNA 的上调,以及膀胱中 B(1)蛋白和脊髓中 B(1)和 B(2)受体蛋白的上调。有趣的是,B(1)和 B(2)蛋白在 SCI 动物的逼尿肌和尿路上皮中的表达分布相似。选择性 B(1)或 B(2)激动剂刺激膀胱,SCI 膀胱的浓度-反应曲线高于对照或假手术膀胱。膀胱测压显示,B(2)选择性拮抗剂 Icatibant 治疗 SCI 动物可减少非排尿收缩(NVC)的幅度和数量。B(1)拮抗剂 Des-Arg(9)-[Leu(8)]-缓激肽减少了 NVC 的数量,而非肽 B(1)拮抗剂 SSR240612 减少了 NVC 的数量、膀胱容量,并增加了排尿效率和排空量。
综上所述,这些数据表明 B(1)和 B(2)受体在 SCI 大鼠 OAB 中起重要作用,并提示阻断这些受体可能是控制 OAB 的潜在治疗靶点。